Other Income & Expense
Interest Income (Expense), Nonoperating
Kailera Therapeutics Interest Income (Expense), Nonoperating increased by 241.3% to $5.72M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
Lower net interest expense indicates reduced debt burden or improved interest rate management, while higher expense signals increased leverage or rising interest rates.
Detailed definition
This represents the net interest expense incurred on corporate debt obligations, offset by interest income earned on cas...
Peer comparison
Standardized across all capital-intensive industries as 'Net Interest Expense'.
Metric ID:
other_income_expense_interest_income_expense_nonoperating_netHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $1.68M | $5.72M |
| QoQ Change | — | +241.3% |
| YoY Change | — | +241.3% |
Range$1.68M – $5.72M
Avg YoY Growth+241.3%
Median YoY Growth+241.3%
Interest Income (Expense), Nonoperating at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's interest income (expense), nonoperating?
- Kailera Therapeutics (KLRA) reported interest income (expense), nonoperating of $5.72M in Q1 2026.
- What does interest income (expense), nonoperating mean?
- The net cost of interest on debt minus interest earned on cash.